AbbVie’s Phase 3 Study on Upadacitinib for Hidradenitis Suppurativa: A Potential Game Changer

Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.

AbbVie is conducting a Phase 3 clinical study titled A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy. The study aims to assess the safety and efficacy of the drug upadacitinib in treating patients with moderate to severe hidradenitis suppurativa (HS) who have not responded to anti-TNF therapy. This research is significant as it could provide a new treatment option for HS, a painful inflammatory skin condition.

The intervention being tested is upadacitinib, an oral tablet already approved for other inflammatory conditions such as ulcerative colitis and rheumatoid arthritis. The study will evaluate its effectiveness in treating HS.

The study is designed as a randomized, placebo-controlled, double-blind trial with a parallel intervention model. Participants are randomly assigned to receive either upadacitinib or a placebo, and neither the participants nor the researchers know who receives which treatment. The primary purpose is to assess treatment efficacy.

The study began on June 21, 2023, and is currently recruiting participants. The primary completion date is not specified, but the last update was submitted on August 13, 2025. These dates are crucial for tracking the study’s progress and potential market impact.

This study update could influence AbbVie’s stock performance positively if the results demonstrate upadacitinib’s efficacy in treating HS, potentially leading to expanded use of the drug. Investors should also consider the competitive landscape, as other companies may be developing similar treatments.

The study is ongoing, and further details can be accessed on the ClinicalTrials portal.